FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.
FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
EXECUTIVE SUMMARY
FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.
Key Takeaways
- FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know.
- FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.
- FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.
Read Complete Original Article
Published originally on Livemint - News
